Correlation Between Tcr2 Therapeutics and Pieris Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Tcr2 Therapeutics and Pieris Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Tcr2 Therapeutics and Pieris Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Tcr2 Therapeutics and Pieris Pharmaceuticals, you can compare the effects of market volatilities on Tcr2 Therapeutics and Pieris Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Tcr2 Therapeutics with a short position of Pieris Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Tcr2 Therapeutics and Pieris Pharmaceuticals.

Diversification Opportunities for Tcr2 Therapeutics and Pieris Pharmaceuticals

-0.36

Correlation Coefficient

Tcr2 Therapeutics  Pieris Pharmaceuticals

Very good diversification

The 3 months correlation between Tcr2 and Pieris is -0.36. Overlapping area represents the amount of risk that can be diversified away by holding Tcr2 Therapeutics and Pieris Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pieris Pharmaceuticals and Tcr2 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Tcr2 Therapeutics are associated (or correlated) with Pieris Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pieris Pharmaceuticals has no effect on the direction of Tcr2 Therapeutics i.e., Tcr2 Therapeutics and Pieris Pharmaceuticals go up and down completely randomly.

Pair Corralation between Tcr2 Therapeutics and Pieris Pharmaceuticals

Given the investment horizon of 90 days Tcr2 Therapeutics is expected to generate 0.68 times more return on investment than Pieris Pharmaceuticals. However, Tcr2 Therapeutics is 1.48 times less risky than Pieris Pharmaceuticals. It trades about 0.07 of its potential returns per unit of risk. Pieris Pharmaceuticals is currently generating about -0.01 per unit of risk. If you would invest  119.00  in Tcr2 Therapeutics on August 31, 2024 and sell it today you would earn a total of  29.00  from holding Tcr2 Therapeutics or generate 24.37% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	21.17%
Values	Daily Returns

Tcr2 Therapeutics  vs.  Pieris Pharmaceuticals

Tcr2 Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Tcr2 Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Tcr2 Therapeutics is not utilizing all of its potentials. The latest stock price agitation, may contribute to short-term losses for the retail investors.

Pieris Pharmaceuticals

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Pieris Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Pieris Pharmaceuticals is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Tcr2 Therapeutics and Pieris Pharmaceuticals

The main advantage of trading using opposite Tcr2 Therapeutics and Pieris Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Tcr2 Therapeutics position performs unexpectedly, Pieris Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pieris Pharmaceuticals will offset losses from the drop in Pieris Pharmaceuticals' long position.

The idea behind Tcr2 Therapeutics and Pieris Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.